Iodinated CT Contrast Agent for BAT-Based Cachexia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for cancer cachexia and precachexia lack specificity and sensitivity, particularly in detecting adipose tissue changes, which are early indicators of the conditions, leading to delayed and inadequate treatment.
Innovation Solution
A CT scan using an iodinated CT contrast agent that can detect changes in brown and beige adipose tissue (BAT) through positive or increased enhancement, allowing for early diagnosis of cachexia or precachexia by imaging BAT activity and white adipose tissue (WAT) browning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for cachexia, then the diagnosis can be made, but the sensitivity and specificity are insufficient, leading to delayed detection
Solution Approach 1:
The patent changes the diagnostic parameter from conventional clinical criteria to imaging-based detection of adipose tissue browning and BAT activity using CT scans with specific contrast agents, enabling earlier and more accurate detection of cachexia
Solution Approach 2:
The patent introduces CT imaging with iodinated contrast agents as an intermediary tool to detect metabolic changes in adipose tissue, serving as a bridge between clinical presentation and physiological changes, allowing for earlier diagnosis before significant weight loss occurs
2Measurement precision
If weight loss criteria are used to diagnose cachexia, then the diagnosis can be made, but the specificity is reduced in overweight and obese patients
Solution Approach 1:
The patent focuses on local changes in adipose tissue characteristics (browning, BAT activity) rather than global weight loss, allowing for specific detection of cachexia-related metabolic changes regardless of a patient's overall body weight or BMI
Solution Approach 2:
The patent shifts from measuring global weight loss to detecting local metabolic changes in adipose tissue through imaging, providing a diagnosis method that is independent of baseline body weight and applicable across diverse patient populations
3Measurement precision
If no imaging method is used for adipose tissue detection, then the diagnostic approach remains simple, but the ability to detect early metabolic changes is lost
Solution Approach 1:
The patent introduces CT imaging with specific contrast agents as an intermediary tool that enables non-invasive detection of adipose tissue metabolic changes, bridging the gap between simple clinical assessment and complex physiological measurements
Solution Approach 2:
The patent utilizes contrast enhancement and tissue density changes visible on CT imaging to detect adipose tissue browning and BAT activity, transforming invisible metabolic changes into visible imaging signals for diagnosis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate diagnosis of cachexia or precachexia, facilitating timely intervention and improving patient outcomes by detecting metabolic changes in adipose tissue.
Implementation Method 1
A CT scan using an iodinated CT contrast agent that can detect changes in brown and beige adipose tissue (BAT) through positive or increased enhancement
Data Source
AI summary
The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and/or beige adipose tissue (BAT).